Abstract
Background
Pooled AB serum is often used as a media supplement for cell culture but it has the
potential to transmit infectious diseases. To avoid this risk, we used autologous
plasma as a media supplement for manufacturing dendritic cells (DCs) for cancer immunotherapy.
We noticed inconsistencies in the DCs and investigated their nature and cause.
Methods
Adenovirus human epidural growth factor receptor 2 (adHER2/neu) DCs for 21 patients
were manufactured from autologous peripheral blood monocytes that were treated with
granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4 for
3 days, transduced with Ad5f35HER2ECTM and then treated with lipopolysaccharide and
interferon (IFN)-γ for 1 day. The cells were cultured in RPMI-1640 supplemented with
either 10% heat inactivated autologous or AB plasma.
Results
Twenty-eight adHER2/neu DCs were manufactured for 21 patients using autologous plasma
and 68 were manufactured for 20 of those patients using AB plasma. The expression
of human epidural growth factor receptor 2 (HER2/neu) was less for DCs manufactured
with autologous plasma (70.3 ± 33.3% versus 86.1 ± 22.8%; P < 0.01). Manufacturing adHER2/neu DCs using monocytes from three healthy subjects and
plasma from one patient with low HER2/neu expression (18%) resulted in low HER2/neu
expression by all three DCs (13%, 16% and 23%). Analysis of the levels of 1322 proteins
in eight plasma samples associated with low HER2/neu expression and in 12 associated
with high HER2/neu expression revealed that the levels of 14 predicted HER2/neu transduction
efficiency.
Conclusion
The manufacture of adHER2/neu DC using autologous plasma as a media supplement resulted
in inconsistent HER2/neu expression. It is likely that variability in the levels of
multiple proteins in autologous plasma contributed to low HER2/neu expression.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions.Blood. 1997; 89: 776-779
- Anaphylaxis to infusion of autologous bone marrow: an apparent reaction to self, mediated by IgE antibody to bovine serum albumin.J Allergy Clin Immunol. 1989; 83: 871-875
- Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells.Cancer Immunol Immunother. 2000; 49: 152-156
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.Lancet. 2015; 385: 517-528
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.Blood. 2010; 116: 4099-4102
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.Blood. 2016; 128: 1688-1700
- TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.Oncoimmunology. 2016; 5 (e1197459)
- Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science. 1989; 244: 707-712
- Analysis of gene expression data using BRB-ArrayTools.Cancer Inform. 2007; 3: 11-17
- Diagnosis of multiple cancer types by shrunken centroids of gene expression.Proc Natl Acad Sci USA. 2002; 99: 6567-6572
- Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.Hum Gene Ther. 2014; 25: 285-300
- Progress and prospects: immune responses to viral vectors.Gene Ther. 2010; 17: 295-304
- Adenoviral vector immunity: its implications and circumvention strategies.Curr Gene Ther. 2011; 11: 307-320
- Chimeric adenoviral vector Ad5F35L containing the Ad5 natural long-shaft exhibits efficient gene transfer into human T lymphocytes.J Virol Methods. 2013; 194: 52-59
- Influence of cell physiological state on gene delivery to T lymphocytes by chimeric adenovirus Ad5F35.Sci Rep. 2016; 6: 22688
Article info
Publication history
Published online: April 11, 2018
Accepted:
March 10,
2018
Received:
January 4,
2018
Identification
Copyright
Published by Elsevier Inc. on behalf of International Society for Cellular Therapy.
